Advantages azilsartan medoxomil in patients with arterial hypertension: how to make a choice and to optimize antihypertensive therapy?
Abstract
About the Authors
T. V. MartynyukRussian Federation
I. E. Chazova
Russian Federation
References
1. Mancia G, Fagard R. Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertension 2013; 31 (7): 1281-357.
2. Collins R, Peto R, Mac Mahon S et al. Blood pressure, stroke, and coronary heart disease: part 2, short - term reductions in blood pressure. Lancet 1990; 335 (8693): 827-38.
3. Forouzanfar M.H, Liu P, Roth G.A et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mmHg, 1990-2015. JAMA 2017; 317 (2): 165-82.
4. Диагностика и лечение артериальной гипертонии. Клинические рекомендации 2013 г. http://webmed.irkutsk.ru/doc/pdf/fedhypert.pdf
5. Леонова М.В., Штейнберг Л.Л., Белоусов Д.Ю. и др. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР IV: приверженность врачей. РМЖ. 2015; 1 (117): 59-66.
6. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно - сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 10: 4-12.
7. Perry C.M. Azilsartan medoxomil: a review of its use in hypertension. Clin Drug Investig 2012; 32: 621-39.
8. Baker W.L, White W.B. Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension. Ann Pharmacother 2011; 45: 1506-15.
9. Ojima M, Igata H, Tanaka M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336: 801-8.
10. Sica D, White W.B, Weber M.A et al. Comparison of the novel angiotensin II receptor blocker azilsartanmedoxomil vs. valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) 2011; 13: 467-72.
11. Bönner G, Bakris G.L, Sica D et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartanmedoxomil compared with the angiotensin - converting enzyme inhibitor ramipril. J Hum Hypertens 2013; 27: 479-86.
12. Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double - blind clinical study. Hypertens Res 2012; 35: 552-8.
13. Chobanian A.V, Bakris G.L, Black H.R et al. National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
14. Dolan E, Stanton A.V, Thom S et al. ASCOT Investigators. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients - an Anglo - Scandinavian cardiac outcomes trial substudy. J Hypertens 2009; 27: 876-85.
15. Остроумова О.Д., Копченов И.И., Щукина Г.Н. Циркадный ритм артериального давления: прогностическая значимость и возможности коррекции на фоне лечения азилсартана медоксомилом // Consilium Medicum. 2015; 17 (5): 8-13.
16. Cuspidi C, Michev I, Meani S et al. Reduced nocturnal fall in blood pressure, assessed by two ambulatory blood pressure monitorings and cardiac alterations in early phases of untreated essential hypertension. J Human Hypertens 2003; 17: 245-51.
17. Pierdomenico S, Bucci A, Costantini F et al. Circadian blood pressure changes and myocardial ischemia in hypertensive patients with coronary artery disease. J Am Coll Cardiol 1998; 31 (7): 1627-34.
18. Timio M, Venanzi S, Lolli S et al."Non - dipper" hypertensive patients and progressive renal insufficiency: a 3-year longitudinal study. Clin Nephrol 1995; 43 (6): 382-7.
19. Bakris G.L, Sica D, Weber M et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.J Clin Hypertens (Greenwich) 2011; 13: 81-8.
20. White W.B, Weber M.A, Sica D et al. Effects of the angiotensin receptor blocker azilsartanmedoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413-20.
21. Takagi H, Mizuno Y, Niwa M et al. A meta - analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction. Hypertension Res 2014; 37: 432-7.
22. Sica D, Bakris G.L, White W.B et al. Blood pressure - lowering efficacy of the fixed - dose combination of azilsartanmedoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich) 2012; 14: 284-92.
23. French C.J, Zaman A.K, Sobel B.E. The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques. J Cardiovasc Pharmacol 2011; 58: 143-8.
24. Kajiya T, Ho C, Wang J et al. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens 2011; 29: 2476-83.
25. Zhao M, Li Y, Wang J et al. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. Diabetes Obes Metab 2011; 13: 1123-9.
26. He H, Yang D, Ma L et al. Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator - activated receptor - delta - dependent pathways. Hypertension 2010; 55: 869-79.
Review
For citations:
Martynyuk T.V., Chazova I.E. Advantages azilsartan medoxomil in patients with arterial hypertension: how to make a choice and to optimize antihypertensive therapy? Systemic Hypertension. 2017;14(2):45-50.
Email this article 